Tumor immunity landscape in non-small cell lung cancer
Even with the great advances in immunotherapy in recent years, the response rate to immune checkpoint inhibitor therapy for non-small cell lung cancer is only about 20%. We aimed to identify new features that would better predict which patients can benefit from an immune checkpoint blocker. This stu...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PeerJ Inc.
2018-03-01
|
| Series: | PeerJ |
| Subjects: | |
| Online Access: | https://peerj.com/articles/4546.pdf |